Narcolepsy Medication Linked to Sleep-Related Eating
A new case report details how a teen experienced sleep-related eating disorder after increasing her sodium oxybate dosage.
Updated on Oct. 7, 2026 in Sleep Disorders
Live Poll
Do you trust pharmaceutical labels to disclose all potential side effects of a prescribed medication?
A 15-year-old girl developed sleep-related eating disorder after her sodium oxybate dosage for narcolepsy was increased to 8 grams nightly. The patient regularly consumed large amounts of food while unresponsive before medical professionals resolved the issue by reducing the dose.
Why it matters
This case highlights potential adverse effects of sodium oxybate, which is widely used to manage narcolepsy symptoms like cataplexy and excessive daytime sleepiness. Understanding these risks is critical for clinicians balancing effective symptom control with patient safety.
A case report of a 15-year-old patient confirmed episodes after a dosage increase to 8 grams, which was subsequently lowered to 7 grams. Data from a 2022 global safety analysis previously identified 185 similar instances of sodium oxybate-associated sleep eating.
The players
Journal of Taibah University Medical Sciences
This peer-reviewed publication documented the specific case of the 15-year-old patient.
The details
The teenage patient frequently left her bed one to two hours after her initial nightly medication dose to consume calorie-dense foods while remaining asleep. She had no recollection of these events, prompting doctors to adjust her regimen to 7 grams per night alongside behavioral modifications.
Timeline
December 2021 marked the end of data collection for the global safety database analysis.
A global database analysis regarding sleep-related eating was published in 2022.
A case report regarding the teen patient was published in October 2026.
The Big Picture
This case report exists within the framework of the FDA-approved safety guidelines for sodium oxybate, which is indicated for patients aged 7 and older. It follows a documented pattern where pediatric clinical trials have previously identified sleepwalking behaviors in 6% of participants.
Patients and caregivers should be aware of potential sleep-related eating behaviors and monitor for any unexplained food consumption during the night. If such symptoms occur, medical providers may recommend dose adjustments or behavioral interventions to ensure safety.
The takeaway
Maintaining close communication with healthcare providers is essential when adjusting dosages for complex neurological conditions. Implementing dietary changes and bedside safety measures can effectively mitigate risks associated with nighttime parasomnias.
Further reading
For more information on managing narcolepsy and its associated conditions, visit our Sleep Disorders section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you trust pharmaceutical labels to disclose all potential side effects of a prescribed medication?
